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1. Introduction 
The immune system plays an important role in surveillance against tumor development, 
and it is widely known that cancer cells protect themselves against the host's anti-tumor 
immune defense. Cancer cells have several means of evading the antitumor immunity, one 
of which is the production of immune modulators such as cytokines and chemokines. These 
factors can either promote or block immune responses. Many of these molecules are used by 
cancer cells to promote tumor progression including cell proliferation, cell migration, matrix 
remodeling, immune suppression and angiogenesis. On the other hand, some molecules are 
involved in immunotherapeutics for the purpose of enhancing and modifying antitumor 
immune responses. 
In basal cell carcinoma (BCC), several cytokines and chemokines and their receptors are 
associated with the development of this cutaneous cancer. There are varying degrees of 
inflammation in BCC. The majority of peritumor inflammatory cells are lymphocytes and 
most are T cells (1). It has been proposed that the tumor microenvironment of BCC is 
generally Th2 dominant. T regulatory cells and immature dendritic cells mediated by Th2 
cytokines cause immunosuppression and decreased immunity to BCC (2). Tumor-associated 
macrophages (TAM), which are polarized to M2 type, are associated with tumor invasion 
and angiogenesis in BCC (3). In this chapter, we focus on cytokines and chemokines which 
may influence and enhance these immunosuppressive networks. 
2. IL-6 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine, which can induce tumor progression by 
manipulating immune responses in the tumor microenvironment. IL-6 is directly related to 
epidermal hyperproliferation in psoriasis (4). There are many experimental evidences that 
IL-6 is associated with BCC. Overexpression of IL-6 in BCC cell lines increases anti-apoptotic 
activity and tumorigenic potency (5). The phosphotidyl inositol 3-kinase (PI3K)/Akt signal 
pathway is involved in such anti-apoptosis (6). On the other hand, IL-6 induces bFGF-
dependent angiogenesis in BCC cell line via JAK/STAT3 and PI3k/Akt pathways (7). IL-6 is 
also involved in CXCL-12 (SDF-1)-enhanced angiogenesis via activating ERK1/2 and NF-κB 
(8). IL-6 expression is associated with a significant increase of IL-8 (CXCL8) expression in 
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BCC (9, 10), one of which functions is tumor angiogenesis. The expression of these two 
cytokines shows a significant positive correlation (10).  
A single nucleotide polymorphism (SNP) in the promoter regions of IL-6 gene (IL6) is 
associated with the risk of BCC. The promoter region of IL6 contains several SNPs, 
including –634G>C, –597G>A and –174G>C. It has been reported that IL6 –597 G>A is 
significantly associated with BCC risk (11). However, others reported that there was no 
difference for genotype distributions of SNPs in the promoter region of IL6 between the 
BCC cases and controls, while linkage disequilibrium was observed between the –174 and 
–597 alleles in the IL6 (12). 
3. IL-10 
Interleukin-10 (IL-10) is a major immunosuppressive cytokine that plays a critical regulatory 
role in several areas of the immune system. It contributes to immunosuppression in the 
tumor microenvironment and may render it permissive for infiltration of cancer cells. IL-10 
is upregulated in both melanoma (13-15) and non-melanoma skin cancer including BCC (2, 
16, 17). The presence of IL-10 in BCC is associated with the lack of expression of HLA-DR, 
ICAM-1, CD40 and CD80 and the inconsistent expression of HLA-ABC in BCC (17). BCC is 
regarded as an indolent (slow growing) cancer with limited metastatic potential. While IL-10 
expression by melanoma cells correlates with melanoma progression and development of 
metastatic competence (18), there is no clear correlation between IL-10 expression and tumor 
invasiveness of BCC. IL-10 can be detected by both aggressive BCC and nonaggressive BCC 
such as superficial BCC. However, there are discrepant results regarding IL-10 expression in 
superficial BCC. Urosevic et al. found that superficial BCC cells were uniformly negative for 
IL-10 expression at baseline and showed little change after imiquimod treatment (19). 
 
Fig. 1. IL-10 mRNA is expressed by tumor cells in basal cell carcinoma (blue/purple color, 
RT in situ PCR). 
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SNP in the promoter regions of IL-10 gene (IL10) is associated with the risk of BCC. IL10 –
1082G>A is detected in BCC (12), and this polymorphism, as well as tumor necrosis 
factor-alpha (TNF-α) gene TNF –308G>A polymorphism, is more prevalent in aggressive 
BCC (20). However, others reported that there was no significant association between 
BCC and IL10 –1082 (11). 
4. CXCL12 and CXCR4 
CXCL12 (SDF-1) is a proinflammatory chemokine produced in response to inflammatory 
stimuli. This chemokine functions as a chemoattractant for lymphocytes. CXCL12 also plays 
an important role in tumor angiogenesis through binding to its receptor, CXCR4. CXCR4 
expression enhances tumorigenesis and angiogenesis in BCC. Such CXCL12-enhanced 
angiogenesis involves the ERK1/2 and NF-κB pathways mediated by IL-6 (8). CXCR4 is 
especially expressed in noduloulcerative and sclerosing types of BCC and is associated with 
more aggressive behavior (21). CXCL12 directs BCC invasion by upregulating gelatinase 
activity of matrix metalloproteinase-13 (MMP-13). The transcriptional regulation of MMP-13 
by CXCL12 is mediated by phosphorylation of ERK1/2 and c-Jun/AP-1 activation (22). 
CXCL12 also upregulates several angiogenesis-associated genes including interferon alpha-
inducible protein 27 (IFI27), bone morphogenetic protein 6 (BMP6) and cyclooxygenase 2 
(COX-2) (8).  
5. CXCL9, CXCL10, CXCL11 and CXCR3 
CXCL9 (MIG), CXCL10 (IP-10) and CXCL11 (I-TAC) are chemokines that are induced by 
interferon during inflammatory responses. These chemokines bind to a common receptor, 
CXCR3. They can promote chemotaxis of activated T cells and NK cells through binding to 
CXCR3. The most recent attention has been given to the role of these chemokines in 
tumorigenesis of BCC. It has been reported that CXCL9, CXCL10, CXCL11, and their receptor 
CXCR3 are significantly upregulated in BCC. CXCR3, CXCL10, and CXCL11, but not CXCL9, 
colocalize with keratin 17, which is a BCC keratinocyte marker. Exposure of BCC cells to 
CXCL11 in vitro enhances keratinocyte cell proliferation (23). CXCL9, CXCL10 and CXCL11 
promote expression of functional indoleamine 2,3-dioxygenase (IDO), which also colocalizes 
with keratin 17 (24). Thus, CXCR3 and its ligands may be important in tumorigenesis of BCC. 
6. IL-8 (CXCL8) 
Interleukin-8 (IL-8, CXCL8) is a chemokine produced by inflammatory cells and other cell 
types. This chemokine is one of the major mediators of the inflammatory response. It functions 
as a chemoattractant, but is also known as an angiogenic factor. IL-8 is associated with tumor 
angiogenesis in many solid tumors. It has been reported IL-8 is highly expressed in BCC (25). 
As described earlier in this chapter, IL-8 expression is associated with a significant increase of 
IL-6 expression in BCC (9, 10), and is positively correlated with IL-6 expression (10). However, 
the detailed mechanisms of IL-8 involved in the development of BCC are not fully understood. 
7. CCL27 
CCL27 is a chemokine that functions as a chemoattractant by interacting with its receptor, 
CCR10. This chemokine regulates T cell homing under homeostatic and inflammatory 
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conditions, and plays a role in T cell-mediated inflammation of the skin. In BCC, the 
downregulating of CCL27 expression is associated with tumor immune escape. A significant 
decrease in CCL27 expression is also observed in squamous cell carcinoma and actinic 
keratosis. These skin tumors may evade T cell-mediated antitumor immune responses by 
down-regulating the expression of CCL27 through the activation of epidermal growth factor 
receptor (EGFR)-Ras-MAPK-signaling pathways (26). 
8. IFN-γ 
Interferon-gamma (IFN-γ) is a cytokine that is critical for immune responses against cancer. 
IFN-γ binding to the receptor activates the JAK-STAT pathway. In BCC, The expression of 
IFN-γ receptor is significantly decreased on the cancer cells compared with the overlying 
epidermis. The absence or paucity of IFN-γ receptor and the absence of intercellular 
adhesion molecule-1 (ICAM-1) may explain the lack of tumor-infiltrating cells and the lack 
of an active cell-mediated immune response in BCC (27). 
On the other hand, Th1 cytokines including IFN-γ play a role in spontaneously regressing 
BCC. Some cases of BCC may show spontaneous regression in the absence of therapy. Such 
spontaneous regression is mediated by activated CD4+ T cells, and IFN-γ is elevated in 
actively regressing BCC (28). There is a significantly increased number of CD4+ T cells 
infiltrating regressing tumors, and the expression of IL-2 receptor, which is an early 
activation marker for T cells is also increased (29). Abundant CD8+ T cells and interferon 
signal transduction is associated with partial host antitumor response (2).  
Imiquimod has been shown to be efficacious as a topical treatment for BCC. Imiquimod is a 
Toll-like receptor 7 (TLR7) agonist, which induces interferon and other cytokines through 
the immune system and stimulates innate and adaptive cell-mediated immunity. Clinical 
studies have demonstrated clinical and histological clearance of superficial BCC after 
treatment with imiquimod 5% cream (30-32). Imiquimod treatment is associated with the 
early appearance of lymphocytes and macrophages. This early response tends to be a mixed 
cellular response of CD4 cells, activated dendritic cells and macrophages, with later 
infiltration by CD8 T cells (33). Application of imiquimod induces a cascade of Th1 
cytokines including IFN-α, TNF-α, IL-1α, IL-12, and IFN-γ, with profound effects on innate 
and adaptive immunity and on immunologic memory and antigen presentation. IFN-γ is 
produced by CD4 and CD8 T cells. IFN-γ is associated with the enhanced expression of 
ICAM-1, promoting the influx of immune cells. Imiquimod treatment also induces a massive 
increase in macrophage peritumoral and intratumoral infiltration (19). Thus, the TLR7-
agonist plays an important role in inducing a lymphocytic infiltrate by promoting specific 
Th1 cellular immune response capable of eliminating cancer cells (34). 
9. FasL (CD95L) and Fas (CD95) 
Fas ligand (FasL, CD95L) belongs to the tumor necrosis factor (TNF) family. FasL binds to 
its receptor, Fas (CD95), and induces apoptosis. Apoptosis via FasL/Fas pathway plays an 
important role in the regulation of the immune system. FasL expressed by cacncer cells 
induces apoptosis of infiltrating lymphocytes and they can evade immune surveillance, 
contributing to cancer progression. BCC has been reported to lack Fas expression (19, 35), 
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while they commonly retain the expression of FasL (36). In normal skin, Fas is expressed by 
keratinocytes in the basal layer. Fas expression is up-regulated in chronically sun-damaged 
skin. Actinic keratosis does not express Fas. Squamous cell carcinoma focally expresses Fas 
at the sites of contact with lymphocytes (35).  
It has been suggested that BCC can evade host immune surveillance by expressing FasL (37). 
However, different results were obtained for the FasL expression in BCC (19, 38, 39), and the 
issue of FasL expression in BCC is still debatable. After imiquimod treatment, the infiltrating 
cells demonstrate an increase in Fas/FasL expression, while Fas expression by BCC cells 
remains unaffected and FasL expression demonstrates either an increase or a decrease in 
different cases (19). After intralesional IFN-α treatment, BCC cells become Fas-positive with 
signs of tumor regression as a result of tumor cell apoptosis (36). Thus, Fas/FasL pathway 
may be associated with tumor regression by such treatments. 
 
Substance Alternative name Receptor Action 
IL-6  IL6R (CD126) Anti-apoptotic activity 
IL-8 CXCL8 
IL8RA (CXCR1, 
CD181); IL8RB 
(CXCR2, CD182) 
Tumor angiogenesis 
IL-10  
IL10RA (CDw210a); 
IL10RB (CDw210b) 
Immune suppression 
CXCL9 MIG CXCR3 (CD183) Tumorigenesis 
CXCL10 IP-10 CXCR3 (CD183) Tumorigenesis 
CXCL11 I-TAC CXCR3 (CD183) Tumorigenesis 
CXCL12   SDF-1 CXCR4 (CD184) 
Tumor angiogenesis; 
stromal invasion  
CCL27 
CTACK, ILC,  
ESKine 
CCR10 
Immune escape by down-
regulation of CCL27 
IFN-γ  IFNGR1 (CD119); 
IFNGR2 
Tumor regression; immune 
escape by down-regulation 
of IFN-γ receptor 
FasL CD95L Fas (CD95) Immune escape 
 
Table 1. Cytokines and chemokines in the pathogenesis of Basal Cell Carcinoma. 
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10. Conclusions 
There is much more work to be done in order to adequately characterize the clinical 
significance of cytokines, chemokines and related molecules in BCC. Studies thus far show 
that the factors described in this chapter play an integral role in BCC development and 
immunosuppression. A better understanding of these interactions may facilitate 
development of more potent immune-based treatment for BCC. 
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